

Application
Number

SEARCH

IDS Flag Clearance for Application

10532245

IDS
Information

Content



Mailroom Date

Entry Number

IDS Review

Reviewer

UPDATE



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

chain bonds :

2-8 4-7

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-14 7-17 8-9 8-13 9-10 10-11 11-12 12-13 14-15
15-16 16-17 16-18 17-21 18-19 19-20 20-21

exact/norm bonds :

1-2 1-6 2-3 2-8 3-4 4-5 4-7 5-6 7-14 7-17 8-9 8-13 9-10 10-11 11-12 12-13
14-15 15-16

normalized bonds :

16-17 16-18 17-21 18-19 19-20 20-21

isolated ring systems :

containing 1 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom

10523,245

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|----|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | SEP 09 | ACD predicted properties enhanced in REGISTRY/ZREGISTRY |
| NEWS | 4 | OCT 03 | MATHDI removed from STN |
| NEWS | 5 | OCT 04 | CA/CAPplus-Canadian Intellectual Property Office (CIPO) added to core patent offices |
| NEWS | 6 | OCT 13 | New CAS Information Use Policies Effective October 17, 2005 |
| NEWS | 7 | OCT 17 | STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAPplus documents for use in third-party analysis and visualization tools |
| NEWS | 8 | OCT 27 | Free KWIC format extended in full-text databases |
| NEWS | 9 | OCT 27 | DIOGENES content streamlined |
| NEWS | 10 | OCT 27 | EPFULL enhanced with additional content |
| NEWS | 11 | NOV 14 | CA/CAPplus - Expanded coverage of German academic research |
| NEWS | 12 | NOV 30 | REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data |
| NEWS | 13 | DEC 05 | CASREACT(R) - Over 10 million reactions available |
| NEWS EXPRESS | | | DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/ |
| NEWS HOURS | | | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | | | General Internet Information |
| NEWS LOGIN | | | Welcome Banner and News Items |
| NEWS PHONE | | | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | | | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:37:25 ON 10 DEC 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

10523,245

| | ENTRY | SESSION |
|---------------------|-------|---------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 10:37:31 ON 10 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 DEC 2005 HIGHEST RN 869698-41-9
DICTIONARY FILE UPDATES: 9 DEC 2005 HIGHEST RN 869698-41-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.



REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10532245.str

10523,245



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
chain bonds :
2-8 4-7
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-14 7-17 8-9 8-13 9-10 10-11 11-12 12-13
14-15 15-16 16-17 16-18 17-21 18-19 19-20 20-21
exact/norm bonds :
1-2 1-6 2-3 2-8 3-4 4-5 4-7 5-6 7-14 7-17 8-9 8-13 9-10 10-11 11-12
12-13 14-15 15-16
normalized bonds :
16-17 16-18 17-21 18-19 19-20 20-21
isolated ring systems :
containing 1 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom


L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

10523,245



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 10:37:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 93 TO 587

PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> d scan


L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 3-Morpholinemethanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI)

MF C19 H24 N8 O2

CI COM


10523,245



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Benzimidazol-5-ol, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI)
MF C20 H22 F2 N6 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI)
MF C21 H25 F2 N7 O2


Relative stereochemistry.

10523,245



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(tetrahydro-2-methyl-1,4-oxazepin-4(5H)-yl)-2-pyrimidinyl]- (9CI)
MF C21 H26 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-6-nitro- (9CI)
MF C20 H21 F2 N7 O4


10523,245



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Benzimidazol-6-amine, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI)
MF C22 H27 F2 N7 O2


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Benzimidazole, 1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI)
MF C20 H25 N7 O2

10523,245



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful

FULL SEARCH INITIATED 10:38:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 301 TO ITERATE

100.0% PROCESSED 301 ITERATIONS

168 ANSWERS

SEARCH TIME: 00.00.01

L3 168 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.76

161.97

FILE 'CAPLUS' ENTERED AT 10:38:39 ON 10 DEC 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Dec 2005 VOL 143 ISS 25

FILE LAST UPDATED: 9 Dec 2005 (20051209/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l4

L4 NOT FOUND

The L-number entered has not been defined in this session, or it

10523,245

has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l3

L4 7 L3

=> d l4 1-7 bib hitstr

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:1103774 CAPLUS

DN 143:367324

TI Preparation of 2-benzimidazolyl-4,6-dimorpholinylpyrimidine and
2-benzimidazolyl-4,6-dimorpholinyltriazine derivatives as antitumor agents
IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Tsuchida,
Yoshio; Saitoh, Kenichi; Watanabe, Tetsuo

PA Zenyaku Kogyo Kabushiki Kaisha, Japan

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2005095389 | A1 | 20051013 | WO 2005-JP6111 | 20050330 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |

PRAI JP 2004-103273 A 20040331

IT 866392-54-3P 866392-55-4P 866392-56-5P

866392-57-6P 866392-58-7P 866392-59-8P

866392-60-1P 866392-61-2P 866392-62-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of 2-benzimidazolyl-4,6-dimorpholinylpyrimidine and 2-benzimidazolyl-4,6-dimorpholinyltriazine derivs. as antitumor agents)

RN 866392-54-3 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10523,245



RN 866392-55-4 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 866392-56-5 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10523,245



RN 866392-57-6 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6R)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 866392-58-7 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-4-methoxy- (9CI) (CA INDEX NAME)

COc1ccc2c(c1)n(c2)C(=N)C(F)F

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-4-methoxy-, rel- (9CI)
(CA INDEX NAME)


CN 1H-Benzimidazole, 2-(difluoromethyl)-4-methoxy-1-[4-(4-morpholinyl)-6-(2,2,5,5-tetramethyl-4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



10523,245


RN 866392-61-2 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-4-ethoxy- (9CI) (CA INDEX NAME)



RN 866392-62-3 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-4-ethoxy- (9CI) (CA INDEX NAME)



IT 866392-64-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 2-benzimidazolyl-4,6-dimorpholinylpyrimidine and 2-benzimidazolyl-4,6-dimorpholinyltriazine derivs. as antitumor agents)

RN 866392-64-5 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-pyrimidinyl]-2-(difluoromethyl)-4-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:370924 CAPLUS

DN 140:375193

TI Preparation of heterocyclic compounds and antitumor drugs containing the same as the active ingredient

IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Tsuchida, Yoshio; Saito, Kenichi; Sasahara, Hiroya; Watanabe, Tetsuo

PA Zenyaku Kogyo Kabushiki Kaisha, Japan

SO PCT Int. Appl., 23 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004037812 | A1 | 20040506 | WO 2003-JP13589 | 20031024 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2503451 | AA | 20040506 | CA 2003-2503451 | 20031024 |
| | EP 1557415 | A1 | 20050727 | EP 2003-758850 | 20031024 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRAI | JP 2002-311086 | A | 20021025 | | |
| | WO 2003-JP13589 | W | 20031024 | | |
| OS | MARPAT 140:375193 | | | | |
| IT | 685111-07-3P | | | | |
| | RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) | | | | |
| | (preparation of 2-(1-benzimidazolyl)-4-morpholino-1,3,5-triazine or -pyrimidine derivs. as antitumor drugs) | | | | |
| RN | 685111-07-3 CAPLUS | | | | |
| CN | 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME) | | | | |




IT **685111-02-8P**, 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholinopyrimidine **685111-03-9P**, 2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine **685111-04-0P**, 2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholino-1,3,5-triazine **685111-05-1P**, 2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-[methyl(1-methylpiperidin-4-yl)amino]-6-morpholino-1,3,5-triazine **685111-06-2P**, 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholino-1,3,5-triazine **685111-08-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(1-benzimidazolyl)-4-morpholino-1,3,5-triazine or -pyrimidine derivs. as antitumor drugs)

RN 685111-02-8 CAPLUS

CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-[2-(hydroxymethyl)-1-pyrrolidinyl]-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 685111-03-9 CAPLUS


CN 1H-Benzimidazol-6-amine, 4-chloro-2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

CN1=CC=C(C=C1C2=NC(=N2)N(C3=NC=NC(=N3)N4CCOCC4)C(F)(F)F)C5=CC=C(C=C5)Cl

CN 2-Pyrrolidinemethanol, 1-[4-[6-amino-4-chloro-2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




CN 1H-Benzimidazol-6-amine, 4-chloro-2-(difluoromethyl)-1-[4-[methyl(1-methyl-4-piperidinyl)amino]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-[2-(hydroxymethyl)-1-pyrrolidinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245



RN 685111-08-4 CAPLUS


CN 1H-Benzimidazol-5-ol, 4-chloro-2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME)



IT **685111-12-0P**, 2-[4-(tert-Butyldimethylsilyloxy)-2-(difluoromethyl)benzimidazol-1-yl]-4-(2-hydroxymethylpyrrolidin-1-yl)-6-morpholinopyrimidine **685111-14-2P**, 2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-1-yl)-4-chloro-6-morpholino-1,3,5-triazine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 2-(1-benzimidazolyl)-4-morpholino-1,3,5-triazine or -pyrimidine derivs. as antitumor drugs)


RN 685111-12-0 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[2-(difluoromethyl)-4-[(1,1-dimethylethyl)dimethylsilyl]oxy]-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 685111-14-2 CAPLUS

CN 1H-Benzimidazol-6-amine, 4-chloro-1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:202751 CAPLUS
 DN 142:176724
 TI Product subclass 3: 1,3,5-triazines and phosphorus analogues
 AU von Angerer, S.
 CS Bad Abbach, 93077, Germany
 SO Science of Synthesis (2004), 17, 449-583
 CODEN: SSCYJ9
 PB Georg Thieme Verlag
 DT Journal; General Review
 LA English
 IT 220229-25-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (review preparation of triazines and their phosphorus analogs via
 cyclization, ring transformation, aromatization, and substituent
 modification)
 RN 220229-25-4 CAPLUS
 CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI)
 (CA INDEX NAME)




RE.CNT 592 THERE ARE 592 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:849619 CAPLUS
 DN 137:370113
 TI Preparation of heterocyclic compounds as antitumor agents
 IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Sasahara,
 Hiroya; Watanabe, Tetsuo
 PA Zenyaku Kogyo Kabushiki Kaisha, Japan
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 2002088112 | A1 | 20021107 | WO 2002-JP4227 | 20020426 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, | | | | |

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2445395 AA 20021107 CA 2002-2445395 20020426
EP 1389617 A1 20040218 EP 2002-722829 20020426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
CN 1538967 A 20041020 CN 2002-812617 20020426
US 2004116421 A1 20040617 US 2003-475094 20031027
PRAI JP 2001-132250 A 20010427
WO 2002-JP4227 W 20020426
OS MARPAT 137:370113
IT **475110-93-1P**, 2-(2-Difluoromethylbenzimidazol-1-yl)-4-morpholino-6-
thiomorpholino-1,3,5-triazine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic compds. as antitumor agents)
RN 475110-93-1 CAPLUS
CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-(4-
thiomorpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



IT **475110-78-2P 475110-79-3P**, 2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine
475110-80-6P, 2-(2-Difluoromethylbenzimidazol-1-yl)-4-morpholino-6-thiomorpholinopyrimidine **475110-81-7P 475110-82-8P**,
2-(2-Difluoromethylbenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholinopyrimidine **475110-83-9P**, 2-(2-Difluoromethylbenzimidazol-1-yl)-4-(2-methylmorpholino)-6-morpholinopyrimidine **475110-84-0P 475110-85-1P**
475110-86-2P 475110-87-3P 475110-88-4P
475110-89-5P 475110-90-8P 475110-91-9P
475110-92-0P, 2-(2-Difluoromethylbenzimidazol-1-yl)-4-(2,3-dimethylmorpholino)-6-morpholino-1,3,5-triazine **475110-94-2P**,
2-(2-Difluoromethylbenzimidazol-1-yl)-4-(2-methylmorpholino)-6-morpholino-1,3,5-triazine **475110-95-3P 475110-96-4P**,
2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine
475110-97-5P 475110-98-6P 475110-99-7P,
2-(2-Acetylamino benzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine
475111-00-3P 475111-01-4P, 2-(2-Formylaminobenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine **475111-02-5P**
475111-03-6P 475111-04-7P 475111-05-8P
475111-06-9P, 2-(2-Methoxycarbonylamino benzimidazol-1-yl)-4,6-

bis(morpholino)-1,3,5-triazine **475111-07-0P 475111-08-1P**
475111-09-2P, 2-(6-Amino-2-difluoromethylbenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine **475111-10-5P**
475111-12-7P, 2-(4-Amino-2-difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine **475111-15-0P**,
 2-(6-Amino-2-difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine **475111-17-2P 475111-19-4P**
475111-21-8P, 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine **475111-23-0P**
 , 2-(2-Difluoromethyl-5-hydroxybenzimidazol-1-yl)-4-(2,2-dimethyloxazolidin-3-yl)-6-morpholino-1,3,5-triazine **475111-25-2P**
 , 2-(2-Difluoromethyl-5-hydroxybenzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as antitumor agents)

RN 475110-78-2 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 475110-79-3 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 475110-80-6 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-(4-thiomorpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


10523,245



RN 475110-81-7 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 475110-82-8 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 475110-83-9 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2-methyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


10523,245



RN 475110-84-0 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-[(5R)-2,2,5-trimethyl-4-morpholinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475110-85-1 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-[(5S)-2,2,5-trimethyl-4-morpholinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 475110-86-2 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10523,245

morpholinyl]-2-pyrimidinyl]-2-(fluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475110-87-3 CAPLUS

CN 1H-Benzimidazole-2-methanol, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 475110-88-4 CAPLUS

CN 1H-Benzimidazole-2-methanol, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(1-piperidinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10523,245



RN 475110-89-5 CAPLUS

CN 1H-Benzimidazole-2-methanol, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-[2-(hydroxymethyl)-1-pyrrolidinyl]-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475110-90-8 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10523,245

RN 475110-91-9 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 475110-92-0 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,3-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 475110-94-2 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2-methyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 475110-95-3 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,5S)-2,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

NAME)

Relative stereochemistry.

C1=CC=C2C(=C1)N=C(N2)C(F)(F)F


Absolute stereochemistry.



RN 475110-98-6 CAPLUS
CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-(1-oxido-4-


10523,245

thiomorpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 475110-99-7 CAPLUS


CN Acetamide, N-[1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 475111-00-3 CAPLUS

CN Acetamide, N-[1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-01-4 CAPLUS

CN Formamide, N-[1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)


10523,245



RN 475111-02-5 CAPLUS

CN Propanamide, N-[1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-03-6 CAPLUS

CN Formamide, N-[1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10523,245

RN 475111-04-7 CAPLUS

CN Formamide, N-[1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-05-8 CAPLUS

CN Formamide, N-[1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazol-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-06-9 CAPLUS

CN Carbamic acid, [1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)


10523,245



RN 475111-07-0 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 475111-08-1 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10523,245




● x HCl

RN 475111-09-2 CAPLUS
CN 1H-Benzimidazol-6-amine, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 475111-10-5 CAPLUS
CN 1H-Benzimidazol-6-amine, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



10523,245


RN 475111-12-7 CAPLUS

CN 1H-Benzimidazol-4-amine, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME)



RN 475111-15-0 CAPLUS


CN 1H-Benzimidazol-6-amine, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 475111-17-2 CAPLUS

CN 1H-Benzimidazol-6-amine, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 475111-19-4 CAPLUS

CN 1H-Benzimidazol-5-ol, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


10523,245

Relative stereochemistry.




RN 475111-21-8 CAPLUS

CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 475111-23-0 CAPLUS

CN 1H-Benzimidazol-5-ol, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-3-oxazolidinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 475111-25-2 CAPLUS

CN 1H-Benzimidazol-5-ol, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



IT **475111-30-9P 475111-33-2P 475111-35-4P 475111-36-5P 475111-38-7P**, 4-Chloro-2-(2-difluoromethylbenzimidazol-1-yl)-6-morpholino-1,3,5-triazine **475111-39-8P**, 2-(2-Aminobenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine **475111-41-2P**, 4-Chloro-2-(2-difluoromethyl-5-nitrobenzimidazol-1-yl)-6-morpholino-1,3,5-triazine **475111-42-3P**, 4-Chloro-2-(2-difluoromethyl-6-nitrobenzimidazol-1-yl)-6-morpholino-1,3,5-triazine **475111-43-4P**, 2-(2-Difluoromethyl-5-nitrobenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine **475111-44-5P**, 2-(2-Difluoromethyl-6-nitrobenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine **475111-45-6P**, 2-(2-Difluoromethyl-5-nitrobenzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine **475111-46-7P**, 2-(2-Difluoromethyl-6-nitrobenzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine **475111-48-9P 475111-49-0P**, 2-(2-Difluoromethyl-5-(tert-butyl dimethylsilyloxy)benzimidazol-1-yl)-4,6-bis(morpholino)pyrimidine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heterocyclic compds. as antitumor agents)
 RN 475111-30-9 CAPLUS
 CN 1H-Benzimidazole, 1-[4-chloro-6-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-2-pyrimidinyl]-2-(difluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-33-2 CAPLUS
 CN 1H-Benzimidazol-2-amine, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10523,245



RN 475111-35-4 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 475111-36-5 CAPLUS


CN 1H-Benzimidazole, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 475111-38-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)- (9CI) (CA INDEX NAME)



RN 475111-39-8 CAPLUS


CN 1H-Benzimidazol-2-amine, 1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME)



RN 475111-41-2 CAPLUS


CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)-5-nitro- (9CI) (CA INDEX NAME)

10523,245




RN 475111-42-3 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-(difluoromethyl)-6-nitro- (9CI) (CA INDEX NAME)




RN 475111-43-4 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-5-nitro- (9CI) (CA INDEX NAME)



RN 475111-44-5 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-6-nitro- (9CI) (CA INDEX NAME)



RN 475111-45-6 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-5-nitro- (9CI) (CA INDEX NAME)

10523,245



RN 475111-46-7 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-6-nitro- (9CI) (CA INDEX NAME)



RN 475111-48-9 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 475111-49-0 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:788207 CAPLUS
DN 134:86200
TI Synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and
benzimidazolylpyrimidine derivatives
AU Matsuno, Toshiyuki; Kato, Masanobu; Sasahara, Hiroya; Watanabe, Tetsuo;
Inaba, Masahiro; Takahashi, Masayuki; Yaguchi, Shin-Ichi; Yoshioka,
Kimitomo; Sakato, Mitsuo; Kawashima, Seiichiro
CS Research Laboratory, Zenyaku Kogyo Co., Ltd., Tokyo, 178-0062, Japan
SO Chemical & Pharmaceutical Bulletin (2000), 48(11), 1778-1781
CODEN: CPBTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English
OS CASREACT 134:86200
IT 220228-62-6P 220228-68-2P 220228-70-6P
220228-90-0P 220228-99-9P 220229-00-5P
220229-05-0P 316806-91-4P 316806-92-5P
316806-93-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and
benzimidazolylpyrimidine derivs.)
RN 220228-62-6 CAPLUS
CN 1H-Benzimidazole, 1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA
INDEX NAME)




RN 220228-68-2 CAPLUS
CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-

10523,245

morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-70-6 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 220228-90-0 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-(1H-benzimidazol-1-yl)-N,N-dimethyl-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 220228-99-9 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10523,245



RN 220229-00-5 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 220229-05-0 CAPLUS


CN 1H-Benzimidazole, 1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 316806-91-4 CAPLUS


CN 1H-Benzimidazole, 1-[4-(2-methyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245



RN 316806-92-5 CAPLUS


CN 1H-Benzimidazole, 1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 316806-93-6 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 220229-25-4P 220229-29-8P 316806-94-7P
316806-95-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and benzimidazolylpyrimidine derivs.)

RN 220229-25-4 CAPLUS


CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245



RN 220229-29-8 CAPLUS


CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 316806-94-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 316806-95-8 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:513689 CAPLUS

DN 133:89550

TI Preparation of benzimidazolyltriazine derivatives as antitumor agents

IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Tsuchida, Yoshio; Sasahara, Hiroya; Watanabe, Tetsuo; Inaba, Masahiro

PA Zenyaku Kogyo Kabushiki Kaisha, Japan

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2000043385 | A1 | 20000727 | WO 2000-JP348 | 20000125 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | JP 1999-16216 | A | 19990125 | | |


OS MARPAT 133:89550

IT 282097-26-1P 282097-27-2P 282097-28-3P
 282097-29-4P 282097-30-7P 282097-31-8P
 282097-32-9P 282097-33-0P 282097-34-1P
 282097-35-2P 282097-36-3P 282097-38-5P
 282097-39-6P 282097-40-9P 282097-41-0P
 282097-42-1P 282097-43-2P 282097-44-3P
 282097-45-4P 282097-46-5P 282097-47-6P
 282097-48-7P 282097-49-8P 282097-50-1P
 282097-51-2P 282097-52-3P 282097-53-4P
 282097-54-5P 282097-55-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and antitumor activity of benzimidazolyltriazine derivs.)

RN 282097-26-1 CAPLUS

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(2,3,6-trimethyl-4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 282097-27-2 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,5S)-2,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

10523,245


Relative stereochemistry.



RN 282097-28-3 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,5R)-2,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 282097-29-4 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(2,3,5,6-tetramethyl-4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 282097-30-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-(2-methyl-1-aziridinyl)-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


10523,245



RN 282097-31-8 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282097-32-9 CAPLUS


CN Morpholine, 4-[[4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 282097-33-0 CAPLUS


CN Proline, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

10523,245




RN 282097-34-1 CAPLUS

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(2,3,6-trimethyl-4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 282097-35-2 CAPLUS


CN 1H-Benzimidazole, 1-[5-(methylthio)-4,6-di-4-morpholinyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 282097-36-3 CAPLUS



CN 1H-Benzimidazole, 1-(5-methyl-4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

10523,245




RN 282097-38-5 CAPLUS

CN 5-Pyrimidineacetic acid, 2-(1H-benzimidazol-1-yl)-4,6-di-4-morpholinyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 282097-39-6 CAPLUS

CN 5-Pyrimidineacetic acid, 2-(1H-benzimidazol-1-yl)-4,6-di-4-morpholinyl-, (9CI) (CA INDEX NAME)




RN 282097-40-9 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-5-(methylthio)-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10523,245




RN 282097-41-0 CAPLUS

CN 1H-Benzimidazole, 1-(5-methoxy-4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI)
(CA INDEX NAME)



RN 282097-42-1 CAPLUS

CN 2-Morpholinepropanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 282097-43-2 CAPLUS

CN 2-Morpholinebutanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)


10523,245



●x HCl

RN 282097-44-3 CAPLUS


CN 2-Morpholinebutanamine, 4-[2-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 282097-45-4 CAPLUS

CN 2-Morpholinemethanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-5,6-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 282097-46-5 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, acetate (ester) (9CI) (CA INDEX NAME)

CC(=O)OCC1CCCN1C2=NC3=C(N2)N=CN(C3)N4C=CC=C5C(=C4)N=CN=C5


CN 2-Thia-5-azabicyclo[2.2.1]heptane, 5-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(tetrahydro-1,4-oxazepin-4(5H)-yl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(3-oxazolidinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



CN 2-Pyrrolidinemethanol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-


10523,245

triazin-2-yl]-, benzoate (ester) (9CI) (CA INDEX NAME)




RN 282097-51-2 CAPLUS

CN 2-Morpholinol, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 282097-52-3 CAPLUS


CN 3-Oxa-6-azabicyclo[3.1.1]heptane, 6-[2-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 282097-53-4 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(tetrahydro-1,4-oxazepin-4(5H)-yl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10523,245




RN 282097-54-5 CAPLUS

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(tetrahydro-2-methyl-1,4-oxazin-4(5H)-yl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 282097-55-6 CAPLUS

CN 1H-Benzimidazole, 1-[4-(1-azetidiny)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



IT 282097-57-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and antitumor activity of benzimidazolyltriazine derivatives)

RN 282097-57-8 CAPLUS


CN Carbamic acid, [3-[4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-morpholinyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

azepin-

in-2-

civs.)

3,5-
(CA




IT 220229-25-4P 220229-29-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and antitumor activity of benzimidazolyltriazine derivs.)


RN 220229-25-4 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220229-29-8 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:96239 CAPLUS

DN 130:153673

TI Preparation of heterocyclic compounds as antitumor agents

IN Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Watanabe, Tetsuo; Inaba, Masahiro

PA Zenyaku Kogyo Kabushiki Kaisha, Japan

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

| | | | | | |
|------|--|----|----------|-----------------|----------|
| PI | WO 9905138 | A1 | 19990204 | WO 1998-JP3308 | 19980724 |
| | W: AU, CA, CN, JP, KR, US | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2297326 | AA | 19990204 | CA 1998-2297326 | 19980724 |
| | AU 9883575 | A1 | 19990216 | AU 1998-83575 | 19980724 |
| | AU 727013 | B2 | 20001130 | | |
| | EP 1020462 | A1 | 20000719 | EP 1998-933922 | 19980724 |
| | EP 1020462 | B1 | 20040211 | | |
| | R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE | | | | |
| | CN 1129597 | B | 20031203 | CN 1998-809385 | 19980724 |
| | ES 2213286 | T3 | 20040816 | ES 1998-933922 | 19980724 |
| | US 6251900 | B1 | 20010626 | US 2000-463214 | 20000121 |
| PRAI | JP 1997-198804 | A | 19970724 | | |
| | WO 1998-JP3308 | W | 19980724 | | |

OS MARPAT 130:153673

IT 220228-61-5P 220228-62-6P 220228-63-7P
 220228-64-8P 220228-65-9P 220228-66-0P
 220228-68-2P 220228-69-3P 220228-70-6P
 220228-71-7P 220228-72-8P 220228-73-9P
 220228-74-0P 220228-75-1P 220228-76-2P
 220228-77-3P 220228-78-4P 220228-79-5P
 220228-80-8P 220228-81-9P 220228-82-0P
 220228-83-1P 220228-84-2P 220228-85-3P
 220228-86-4P 220228-87-5P 220228-88-6P
 220228-89-7P 220228-90-0P 220228-91-1P
 220228-92-2P 220228-93-3P 220228-94-4P
 220228-95-5P 220228-96-6P 220228-97-7P
 220228-98-8P 220228-99-9P 220229-00-5P
 220229-01-6P 220229-02-7P 220229-04-9P
 220229-05-0P 220229-07-2P 220229-14-1P
 220229-15-2P 220229-16-3P 220229-18-5P
 220229-20-9P 220229-21-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as antitumor agents)

RN 220228-61-5 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-62-6 CAPLUS


10523,245

CN 1H-Benzimidazole, 1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (9CI) (CA INDEX NAME)




RN 220228-63-7 CAPLUS

CN 1H-Benzimidazole, 1-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 220228-64-8 CAPLUS

CN 1,3,5-Triazine-2-carbonitrile, 4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 220228-65-9 CAPLUS


CN 4-Piperidinol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



10523,245

RN 220228-66-0 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-[3-(trifluoromethyl)-4-morpholinyl]-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-68-2 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-69-3 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10523,245

RN 220228-70-6 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-71-7 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-[(3S,5R)-3,5-dimethyl-4-morpholinyl]-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 220228-72-8 CAPLUS


CN 1H-Benzimidazole, 1-[4-(3,3-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-73-9 CAPLUS


10523,245

CN 1H-Benzimidazole, 1-[4-(3-ethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-74-0 CAPLUS


CN 1H-Benzimidazole, 1-[4-[3-(chloromethyl)-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-75-1 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5R)-3,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-76-2 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(1-piperidinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245




RN 220228-77-3 CAPLUS

CN 1H-Benzimidazole, 1-[4-(3-methyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 220228-78-4 CAPLUS

CN 1H-Benzimidazole, 1-[4-(3-methyl-4-morpholinyl)-6-(1-piperazinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-79-5 CAPLUS


CN Carbamic acid, [[4-[4-(1H-benzimidazol-1-yl)-6-(1-piperazinyl)-1,3,5-triazin-2-yl]-3-morpholinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



10523,245


RN 220228-80-8 CAPLUS

CN 1H-Benzimidazole, 5,6-dimethyl-1-[4-(4-morpholinyl)-6-(1-piperazinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 220228-81-9 CAPLUS

CN 3-Morpholinemethanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(1-piperazinyl)-1,3,5-triazin-2-yl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 220228-82-0 CAPLUS

CN 1H-Benzimidazole, 1-[4-[3-(fluoromethyl)-4-morpholinyl]-6-(1-piperazinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 220228-83-1 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10523,245



RN 220228-84-2 CAPLUS


CN 3-Morpholinemethanol, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-85-3 CAPLUS

CN 1H-Benzimidazole, 1-[4,6-bis[(3R,5S)-3,5-dimethyl-4-morpholinyl]-1,3,5-triazin-2-yl]-2,5,6-trimethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-86-4 CAPLUS


CN 3-Piperidinol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245




RN 220228-87-5 CAPLUS

CN 4-Piperidinone, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220228-88-6 CAPLUS


CN 4-Piperidinol, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 220228-89-7 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-methyl-1-piperazinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)

10523,245




RN 220228-90-0 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-(1H-benzimidazol-1-yl)-N,N-dimethyl-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 220228-91-1 CAPLUS

CN Ethanol, 2-[[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]methylamino]- (9CI) (CA INDEX NAME)




RN 220228-92-2 CAPLUS

CN Ethanol, 2,2'-[[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]imino]bis- (9CI) (CA INDEX NAME)




RN 220228-93-3 CAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)




RN 220228-94-4 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-(1H-benzimidazol-1-yl)-N-ethyl-6-(4-morpholinyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 220228-95-5 CAPLUS

CN Carbamic acid, [4-[1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-3-piperidinyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 220228-96-6 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-6-(4-thiomorpholinyl)-1,3,5-triazin-2-yl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10523,245



RN 220228-97-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220228-98-8 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(3R,5R)-3,5-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10523,245

RN 220228-99-9 CAPLUS

CN 1H-Benzimidazole, 1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 220229-00-5 CAPLUS


CN 1H-Benzimidazole, 1-[4-[(2R,3R)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 220229-01-6 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(4-thiomorpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



10523,245


RN 220229-02-7 CAPLUS

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(1-piperazinyl)-2-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 220229-04-9 CAPLUS

CN Carbamic acid, [[4-[2-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-4-pyrimidinyl]-3-morpholinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 220229-05-0 CAPLUS


CN 1H-Benzimidazole, 1-(4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 220229-07-2 CAPLUS


CN 1H-Benzimidazole, 1,1'-[6-(4-morpholinyl)-2,4-pyrimidinediyl]bis- (9CI)
(CA INDEX NAME)

10523,245




RN 220229-14-1 CAPLUS

CN 1H-Benzimidazole, 1-(5-bromo-4,6-di-4-morpholinyl-2-pyrimidinyl)- (9CI)
(CA INDEX NAME)



RN 220229-15-2 CAPLUS

CN 3-Morpholinemethanamine, 4-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 220229-16-3 CAPLUS

CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(1-piperazinyl)-1,3,5-triazin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)


10523,245



● HCl

RN 220229-18-5 CAPLUS


CN 1H-Benzimidazole, 1-[4-(4-morpholinyl)-6-(1-piperazinyl)-2-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 220229-20-9 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-(1H-benzimidazol-1-yl)-N-ethyl-6-(4-morpholinyl)-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 220229-21-0 CAPLUS

CN 3-Piperidinebutanamine, 1-[4-(1H-benzimidazol-1-yl)-6-(4-morpholinyl)-

10523,245

1,3,5-triazin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 220229-25-4P 220229-29-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as antitumor agents)


RN 220229-25-4 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (9CI) (CA INDEX NAME)



RN 220229-29-8 CAPLUS

CN 1H-Benzimidazole, 1-[4-chloro-6-(4-morpholinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

24.18

186.15

STN INTERNATIONAL LOGOFF AT 10:39:18 ON 10 DEC 2005